by Marisa Wexler, MS | Mar 18, 2026 | Myeloma News
Researchers have developed a new cell therapy that aims to treat endometrial cancer by targeting cancer cells while also depleting immune cells that help protect the tumor. The therapy showed strong anticancer activity in multiple laboratory models, and researchers...
by Marisa Wexler, MS | Mar 17, 2026 | Myeloma News
Add-on treatment with mezigdomide significantly delayed cancer progression among people with hard-to-treat myeloma in a Phase 3 clinical trial, according to interim data announced by the experimental oral therapy’s developer, Bristol Myers Squibb. “We are excited by...
by Marisa Wexler, MS | Mar 16, 2026 | Myeloma News
Sellas Life Sciences is seeking people with newly diagnosed acute myeloid leukemia (AML) for a clinical trial testing its experimental anticancer therapy SLS009 (tambiciclib). The Phase 2 clinical trial (NCT04588922) is expected to enroll about 80 participants,...
by MM360 Staff | Mar 16, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Mar 15, 2026 | Publications
Cancers (Basel). 2026 Feb 26;18(5):755. doi: 10.3390/cancers18050755. ABSTRACT Background/Objectives: Ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma is typically administered inpatient (IP) to monitor for cytokine release syndrome (CRS)...
